Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Medical Tourism Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global medical tourism market was valued at USD 16,761 million in 2018, and it is expected to reach USD 27,247.6 million by 2024, while registering a CAGR of 8.5% during the forecast period, 2019-2023. The factors associated with the growth of the market include higher treatment cost in developed countries, availability of the latest medical technologies, growing compliance on international quality standards, high quality of service, health insurance portability, and advertising and marketing of the medical tourism.
The cost of undergoing medical treatment in a developed country is very high. It is estimated that although the treatments are of reliable quality, the procedures tend to be on the expensive side. Along with this, the major healthcare products are also quite extravagantly priced. This scenario places a big burden on the healthcare systems, worldwide, accompanied by the additional rising costs of litigation during recent times. Healthcare practitioners need to be aware of both the direct and indirect costs and consider how the implementation of prevention protocols may offer cost savings in the longer term. People in developed countries cannot afford the huge expenditure associated with medical treatments. Not all medical bills are covered by insurance companies, which makes the patients turn to countries abroad. Countries in Asia, the Middle East, and South America provide high-quality medical services at a much lower rate, as compared to the developed economies. There are companies that cater to all the medical and non-medical needs of the tourist during their travel.
Scope of the Report
As per the scope of the report, medical tourism is an improvement of the healthcare system, which provides quality medical care to people seeking treatment. Patients travel to other countries for obtaining good medical treatment.
Key Market Trends
Fertility Treatments Segment Expected to Have Highest CAGR
The fertility treatments segment of the medical tourism market is believed to show the fastest growth over the forecast period. The segment is expected to record a CAGR of 9.7% over the forecast period. Fertility treatment is one of the most common treatments for which medical tourists elect to travel across international borders. Fertility tourism or reproductive tourism is one of the fastest-growing areas.
About 20,000 to 25,000 couples annually seek assisted reproductive technology services abroad. An estimated 4.0% of European Union citizens receive treatment in other countries. Fertility treatment procedures are regulated in most European countries.
Asia-Pacific Currently Dominates the Market
The Asia-Pacific region currently dominates the medical tourism market and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the raised preference of medical tourism across the developing countries of this region. China holds the majority of the market in the Asia-Pacific region. This is due to the lower cost of the treatment in China and the better healthcare services provided.
Competitive Landscape
The global medical tourism market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and quality service provision, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices. Companies, like Healthbase, Apollo Hospitals, KPJ Healthcare, and Klinikum Medical Link hold the significant market share in the medical tourism market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Treatment Cost in Developed Countries
4.2.2 Availability of Latest Medical Technologies
4.2.3 Growing Compliance on International Quality Standards
4.2.4 High Quality of Service
4.2.5 Health Insurance Portability
4.2.6 Advertising and Marketing
4.3 Market Restraints
4.3.1 Ethical Concerns
4.3.2 Epidemic Outbreaks
4.3.3 Issues with Patient Follow Up and Post-procedure Complications
4.3.4 Medical Record Transfer Issues
4.4 Industry Attractiveness of Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Cosmetic Treatment
5.1.2 Dental Treatment
5.1.3 Cardiovascular Treatment
5.1.4 Orthopedics Treatment
5.1.5 Bariatric Surgery
5.1.6 Fertility Treatment
5.1.7 Ophthalmic Treatment
5.1.8 Other Treatments
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 France
5.2.2.2 Germany
5.2.2.3 United Kingdom
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Medretreat
6.1.2 Healthbase
6.1.3 Apollo Hospitals
6.1.4 KPJ Healthcare Behard
6.1.5 Klinikum Medical Link
6.1.6 Euromedical Tours
6.1.7 BB Health Solutions
6.1.8 Cosmedic Travel
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment Type
Cosmetic Treatment
Dental Treatment
Cardiovascular Treatment
Orthopedics Treatment
Bariatric Surgery
Fertility Treatment
Ophthalmic Treatment
Other Treatments
Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Asia-Pacific Hemodynamic Monitoring Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 84 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 84 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the Asia-Pacific hemodynamic monitoring market are an increase in the number of critically ill geriatric population and rising prevalence of cardiac disorders and diabetes. According to the economic and social commissions for Asia and Pacific, the percentage of people aged 65 years or older is projected to increase from an estimated 16.8% of people out of the total population in 2016, to nearly 23.3% of the population by 2050, in the Asia-Pacific region. Age is associated with a progressive decline of the functional reserve of multiple organ systems. It is, therefore, not surprising that elderly patients may utilize a disproportionate share of healthcare resources, as approximately 92% of older adults have at least one chronic disease, and 77% have at least two. Early and effective hemodynamic management with fluid therapy and administration of vasoactive drugs to maintain vital organ perfusion and oxygen delivery is mandatory in critically ill patients. This is expected to increase the demand for hemodynamic monitoring, which, in turn, may drive the Asia-Pacific hemodynamic monitoring market.
The market is also propelling due to the increase in the number of reported cases of lifestyle-related diseases, like diabetes, obesity, COPD, and cardiac myopathy, among many others, which require medical monitoring by healthcare professionals, in the Asia-Pacific region. Therefore, the rise in the prevalence of cardiac disorders and diabetes is directly proportional to the growth of the hemodynamic monitoring market.
Scope of the Report
As per the scope of this report, hemodynamic monitoring devices are used to measure the blood pressure inside the veins, heart, and arteries. These devices are also used to monitor the blood flow and the concentration of oxygen in the blood.
Key Market Trends
Non-invasive Monitoring Systems is the Segment under Type of System that is Expected to Grow Fastest During the Forecast Period
Invasive monitoring systems dominated the Asia-Pacific hemodynamic monitoring market, as they provide critical care, allow detailed determinations of cardiorespiratory variables, and are used for the effective preoperative assessment of high-risk patients.
The non-invasive hemodynamic monitoring systems segment is expected to register a CAGR of 10%. In the coming years, the non-invasive hemodynamic monitoring system market is expected to witness the highest growth, with China, Japan, and India positioned as growth engines. According to the American Diabetic Association, around 60% of the world’s diabetic population lives in Asia. The prevalence of diabetes in India and China is 8.6% and 9.6%, respectively. India is known as the diabetes capital of the world with more than 60 million diabetics in the country, as of 2014. There is a high growth in the aging population and high prevalence of diabetes and cardiac diseases, which have helped drive the non-invasive hemodynamic monitoring system market.
Competitive Landscape
The Asia-Pacific hemodynamic monitoring market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in the Critically Ill Geriatric Population
4.2.2 Rise in the Prevalence of Cardiac Disorders and Diabetes
4.3 Market Restraints
4.3.1 Increased Incidences of Complications Associated with Invasive Monitoring Systems
4.3.2 Precision of Co-determinations Adversely Affected Under Low Flow Conditions
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 System Type
5.1.1 Minimally Invasive Monitoring Systems
5.1.2 Invasive Monitoring Systems
5.1.3 Non-invasive Monitoring Systems
5.2 Application
5.2.1 Laboratory-based Monitoring Systems
5.2.2 Home-based Monitoring Systems
5.2.3 Hospital-based Monitoring Systems
5.3 Product Type
5.3.1 Cardiac Output Monitors
5.3.2 Catheters
5.3.3 Connecting Tubes
5.3.4 Guidewires
5.3.5 IV Fluids
5.3.6 Transducers
5.3.7 Other Product Types
5.4 Geography
5.4.1 Asia-Pacific
5.4.1.1 China
5.4.1.2 Japan
5.4.1.3 India
5.4.1.4 Australia
5.4.1.5 South Korea
5.4.1.6 Rest of Asia-Pacific
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Edwards Life Sciences Corporation
6.1.2 LiDCO Group PLC
6.1.3 ICU Medical Inc.
6.1.4 Schwarzer Cardiotek Gmbh
6.1.5 Koninklijke Philips NV
6.1.6 Cheetah Medical Inc
6.1.7 Getinge AB
6.1.8 GE Healthcare
6.1.9 Dragerwerk AG & Co. KGaA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
System Type
Minimally Invasive Monitoring Systems
Invasive Monitoring Systems
Non-invasive Monitoring Systems
Application
Laboratory-based Monitoring Systems
Home-based Monitoring Systems
Hospital-based Monitoring Systems
Product Type
Cardiac Output Monitors
Catheters
Connecting Tubes
Guidewires
IV Fluids
Transducers
Other Product Types
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Computational Biology Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global computational biology market was valued at USD 2,327.06 million in 2018, and is estimated to be valued at USD 6,790.06 million in 2024, witnessing a CAGR of 19.54%. Factors that are responsible for the growth of the market include increase in bioinformatics research, increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and growth of drug designing and disease modeling.
Bioinformatics is recognized as part of the essential knowledge base of numerous career paths in biomedical research and healthcare. The field of bioinformatics and computational biology has gone through a number of transformations over the past 15 years, establishing itself as a key component of new biology. The use of bioinformatics tools in life sciences has become necessary to analyze experimental data. The huge amounts of data pose a challenge for the biological community, as most biologists are not familiar with informatics and statistical interpretation. An interdisciplinary collaboration was started with an aim to address the need for biologists to understand biological data.
Recent improvements in bioinformatics include capacity-building through activities, such as research funding and training opportunities. Increased funding in bioinformatics is helping in creating more advancements in the field of computational biology.
Scope of the Report
Computational biology uses biological data for developing algorithms to understand biological systems and relationships.
Key Market Trends
Commercial Sub-segment is Expected to hold its Highest Market Share in the End User Segment
In the end user segment of the market, the commercial sub-segment is believed to have the largest market size and is expected to witness a CAGR of 19.87% during the forecast period.
Computational biology has a wide range of applications in the fields of genomics, proteomics, pharmacogenomics, and drug discovery. For drug discovery and clinical trials, many companies approach third-party services, who have to maintain computational biology setups for carrying out various drug discovery processes. Many third-party services and small laboratories that maintain computational biology setups are expected to gain huge profits, as they successfully reduce the overall time needed for drug discovery and various other scientific experiments.
The software and databases are relatively costlier, and the cost of drug discovery processes vary across countries, which makes many industries opt for outsourcing, thereby, leading to an increased demand for small laboratories and other commercial companies. Hence, with the increase in bioinformatics research, the increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and the growth of drug designing, disease modeling, and personalized medicine, the demand for computational biology for commercial purposes is expected to increase, thereby, driving the market during the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for computational biology and is expected to continue its stronghold for a few more years. The United States is the leading nation in the field of synthetic biology, which is an emerging discipline involving the creation, control, and reprogramming of biological systems. Since 2005, the US government has channeled more than USD 1 billion for the development of computational biology and synthetic biology. The annual average expenditure for the development of computational biology, by the US government, has been estimated to be USD 140 million.
The overall market for computational biology in the United States is scheduled to grow manifold, over the forecast period, primarily due to high expenditure in drug development endeavors (highest in the world).
Competitive Landscape
The computational biology market is expected to become highly competitive in the near future, as it consists of several major players. With increasing technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices. Companies, like Dassault Systems, Chemical Computing Group Inc., Leadscope Inc., Compugen Ltd, and Rhenovia Pharma SAS, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Bioinformatics Research
4.2.2 Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics
4.2.3 Growth of Drug Designing and Disease Modeling
4.3 Market Restraints
4.3.1 Lack of Trained Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Application
5.1.1 Cellular and Biological Simulation
5.1.1.1 Computational Genomics
5.1.1.2 Computational Proteomics
5.1.1.3 Pharmacogenomics
5.1.1.4 Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
5.1.2 Drug Discovery and Disease Modelling
5.1.2.1 Target Identification
5.1.2.2 Target Validation
5.1.2.3 Lead Discovery
5.1.2.4 Lead Optimization
5.1.3 Preclinical Drug Development
5.1.3.1 Pharmacokinetics
5.1.3.2 Pharmacodynamics
5.1.4 Clinical Trials
5.1.4.1 Phase I
5.1.4.2 Phase II
5.1.4.3 Phase III
5.1.5 Human Body Simulation Software
5.2 By Tool
5.2.1 Databases
5.2.2 Infrastructure (Hardware)
5.2.3 Analysis Software and Services
5.3 By Service
5.3.1 In-house
5.3.2 Contract
5.4 By End User
5.4.1 Academics
5.4.2 Industry
5.4.3 Commercial
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Dassault Systèmes SE
6.1.2 Certara
6.1.3 Chemical Computing Group ULC
6.1.4 Compugen Ltd
6.1.5 Rosa & Co. LLC
6.1.6 Genedata AG
6.1.7 Insilico Biotechnology AG
6.1.8 Leadscope Inc.
6.1.9 Nimbus Discovery LLC
6.1.10 Strand Life Sciences
6.1.11 Schrodinger
6.1.12 Simulation Plus Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Application
Cellular and Biological Simulation
Computational Genomics
Computational Proteomics
Pharmacogenomics
Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
Drug Discovery and Disease Modelling
Target Identification
Target Validation
Lead Discovery
Lead Optimization
Preclinical Drug Development
Pharmacokinetics
Pharmacodynamics
Clinical Trials
Phase I
Phase II
Phase III
Human Body Simulation Software
By Tool
Databases
Infrastructure (Hardware)
Analysis Software and Services
By Service
In-house
Contract
By End User
Academics
Industry
Commercial
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Nuclear Medicine Radioisotopes Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 119 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 119 pages
- Published: 07-06-2019
Market Overview
Increasing cases of cancer and cardiac ailments are the major drivers for the nuclear medicines radioisotopes market. Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics. They meet the statutory definition of drugs under Section 1861(t) of the Social Security Act because they either are included in the various drug compendia or recognized by hospital medical staff as drugs. Historically, nuclear medicine has been well established as a therapeutic modality for thyroid cancer, Graves’ disease, hyperthyroidism, and bone pain palliation, associated with skeletal metastasis. Hence, the broadening applications of radioisotopes are expected to propel market growth.
Scope of the Report
As per the scope of the report, medical radioisotopes are defined as safe radioactive substances that are primarily used in the diagnosis of medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt, since the rays can decay as soon as the imaging is completed.
Key Market Trends
Oncology Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
Radiotherapy can be used to treat various medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used for a clinical role in oncology, with fluorine-18 as the tracer, and is proven to be the most accurate non-invasive method of detecting and evaluating most cancers. A new field for cancer treatment is targeted alpha therapy (TAT) or alpha radio-immunotherapy, especially for the control of dispersed cancers. Nuclear medicine is proven effective in oncology in several roles, spanning the course of the disease, including the characterization of a mass, staging, restaging, and monitoring of therapeutic response. Hence, owing to these associated factors, the oncology segment is expected to exhibit the fastest growth rate.
North America captured the Largest Market Share and is Expected to Retain its Dominance
North America captured the largest market share in the nuclear medicine radioisotopes market. The United States was the largest contributor to the revenue of North America, and is expected to retain its dominance owing to the higher procedural volume and increasing adoption of the nuclear medicine isotopes for various therapeutic applications. Bone scintigraphy is the next most common nuclear medicine procedure performed in the United States, but it represents only 17% of procedures. The volume of PET procedures in the United States is approximately 1.5 million per year. Oncology accounts for more than 90% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 4% each. Canada is the largest producer of Technetium-99m. Due to the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. 80% of the nuclear medicine market is driven by Tc-99m in various diagnostic procedures and treatments. Considering these factors associated with the United States and Canada, the North American market is expected to experience accelerated growth rates and market dominance.
Competitive Landscape
There is high competition among the players of the global nuclear medicine radioisotopes market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. GE Healthcare,NTP Radioisotopes SOC Ltd, Nordion (Canada) Inc., Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Cancer and Cardiac Disorders
4.2.2 Widening Applications of Nuclear Medicine
4.2.3 Increasing SPECT and PET Applications
4.2.4 Increasing Patient Awareness for Healthcare
4.3 Market Restraints
4.3.1 Reimbursement Complications
4.3.2 Regulatory Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Type of Radioisotopes
5.1.1 Technetium-99m (Tc-99m)
5.1.2 Thallium-201 (Tl-201)
5.1.3 Iodine (I-123)
5.1.4 Fluorine-18
5.1.5 Rubidium-82 (Rb-82)
5.1.6 Iodine-131 (I-131)
5.1.7 Lutetium-177 (Lu-177)
5.1.8 Radium-223 (Ra-223) & Alpharadin
5.1.9 Actinium-225 (Ac-225)
5.1.10 Others
5.2 Application
5.2.1 Oncology
5.2.2 Cardiology
5.2.3 Lymphoma
5.2.4 Thyroid
5.2.5 Neurology
5.2.6 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of the World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agfa-Gevaert Group
6.1.2 Cardiarc Ltd
6.1.3 Digirad Corporation
6.1.4 CMR Naviscan (Gamma Medica Inc.)
6.1.5 GE Healthcare
6.1.6 Positron Corp.
6.1.7 Segami Corporation
6.1.8 Siemens Healthcare GmBH
6.1.9 Nordion (Canada) Inc.
6.1.10 NTP Radioisotopes SOC Ltd
6.1.11 Bracco S.p.A
6.1.12 Cardinal Health Inc.
6.1.13 Curium
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Type of Radioisotopes
Technetium-99m (Tc-99m)
Thallium-201 (Tl-201)
Iodine (I-123)
Fluorine-18
Rubidium-82 (Rb-82)
Iodine-131 (I-131)
Lutetium-177 (Lu-177)
Radium-223 (Ra-223) & Alpharadin
Actinium-225 (Ac-225)
Others
Application
Oncology
Cardiology
Lymphoma
Thyroid
Neurology
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Europe Genetic Testing Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 84 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 84 pages
- Published: 07-06-2019
Market Overview
Genetic testing has been growing at an unprecedented rate; a large panel of tests are now available to screen a number of genetic diseases. Treatment is available for a number of rare genetic diseases and the procedure is gaining importance in scenarios, such as carrier testing, newborn screening, predictive and pre-symptomatic testing, etc. Technologies, such as next-generation sequencing, allow one to carry out a large number of genetic tests rapidly and create databases with information about rare genetic diseases. The European countries have undertaken a number of initiatives to increase awareness among people about the benefits of genetic testing.
There are a number of favorable and collaborative policies that are being implemented by the governments to incorporate genetic testing into the healthcare system and to make insurance reimbursements available to citizens. Cancer genetic testing, Alzheimer’s disease testing, and cystic fibrosis testing are the most popular screening tests being carried out in Europe. Till date, genetic testing is being done for a majority of 50 identified hereditary cancer syndromes. Out of them, some of the most common ones include hereditary breast cancer and ovarian cancer syndromes, Li-Fraumeni syndrome, Cowden syndrome, Lynch syndrome, Familial adenomatous polyposis, and retinoblastoma, among others. The practice of genetic testing for hereditary cancer syndromes has changed dramatically in the recent years. In developed countries, like Germany, France, etc., the demand for genetic testing to detect cancer risks is driving the growth of the market. The high GDP expenditure on healthcare, per capita expenditure, increase in awareness among the people, and high income of the citizens are the factors that drive the market in European countries.
Scope of the Report
As per the scope of this report, genetic testing is a test performed to identify the presence of a particular gene/s with a particular sequence of the genome. The gene/s can be identified either directly through sequencing or indirectly through various methods.
Key Market Trends
Diagnostic testing is the segment under type of testing that is expected to grow fastest during the forecast period
Predictive and presymptomatic testing dominated the European genetic testing market system, as it is utilized for the detection of gene mutations related to disorders that appear after birth, frequently in later stages of life. Such tests can be of assistance to individuals having a family member with a genetic disorder, though they are free of any features of the disorder while testing.
Diagnostics testing is expected to register a CAGR of 14.29%, as it is used to diagnose or rule out a specific genetic condition. In most cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical mutations and symptoms. Furthermore, companies, such as Centogene and NIMGenetics, offer a wide range of genetic diagnostic services in Europe, which is further accelerating the growth of the market.
Competitive Landscape
The European genetic testing market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
4.2.2 Increasing Demand for Personalized Medicine
4.2.3 Increasing Application of Genetic Testing in Oncology
4.3 Market Restraints
4.3.1 High Costs of Genetic Testing
4.3.2 Social and Ethical Implications of Genetic Testing
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Newborn Screening
5.1.4 Predictive and Presymptomatic Testing
5.1.5 Prenatal Testing
5.1.6 Nutrigenomic Testing
5.2 Disease
5.2.1 Alzheimer’s Disease
5.2.2 Cancer
5.2.3 Cystic Fibrosis
5.2.4 Sickle Cell Anemia
5.2.5 Duchenne Muscular Dystrophy
5.2.6 Thalassemia
5.2.7 Huntington’s Disease
5.2.8 Special Disease
5.2.9 Other Diseases
5.3 Technology
5.3.1 Cytogenetic Testing
5.3.2 Biochemical Testing
5.3.3 Molecular Testing
5.4 Geography
5.4.1 Europe
5.4.1.1 Germany
5.4.1.2 United Kingdom
5.4.1.3 France
5.4.1.4 Italy
5.4.1.5 Spain
5.4.1.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Illumina Inc.
6.1.2 Abbott Laboratories
6.1.3 23andMe Inc.
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Qiagen
6.1.6 Blueprint Genetics Oy
6.1.7 Eurofins Scientific
6.1.8 Centogene AG
6.1.9 Thermo Fisher Scientific
6.1.10 Elitech Group
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Type
Carrier Testing
Diagnostic Testing
Newborn Screening
Predictive and Presymptomatic Testing
Prenatal Testing
Nutrigenomic Testing
Disease
Alzheimer’s Disease
Cancer
Cystic Fibrosis
Sickle Cell Anemia
Duchenne Muscular Dystrophy
Thalassemia
Huntington’s Disease
Special Disease
Other Diseases
Technology
Cytogenetic Testing
Biochemical Testing
Molecular Testing
Geography
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
South Africa Minimally Invasive Surgical Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 74 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 74 pages
- Published: 07-06-2019
Market Overview
The major factors for the growth of the South African minimally invasive surgical devices market include the higher acceptance rate of minimally invasive procedures over traditional procedures, improved patient quality of life and increasing number of surgeries among the aging population, minimally invasive surgeries help reduce healthcare costs and time, and increasing prevalence of lifestyle-related and chronic disorders.
Minimally invasive surgeries (MIS) have been reported to cause less post-operative pain, and hence, patients receive smaller dosages of painkillers. As there are minimal cuts or stitches involved, the hospital stay is relatively shorter, and patients need not visit the hospital frequently. Traditional open surgeries involve long incisions made through the muscles, and these muscles take a considerable amount of time to heal, whereas MIS procedures involve smaller incisions, leading to quicker recovery. In addition, the body scars involved in MIS are barely noticeable. The main advantage that MIS has over traditional open surgeries is higher precision, due to video-assisted equipment, which produces a better and magnified image of the organs or body parts being operated. These surgeries are gaining wider acceptance among the geriatric population, due to the relatively shorter recovery time. These developments have created significant traction for robotic surgeries in several private hospitals in South Africa. Most of the initial surgeries performed using these robotic systems were to treat cardiovascular, urology, and neurology conditions. Furthermore, with improvements in the reimbursement scenario and streamlining of regulatory guidelines, the MIS devices market is expected to grow significantly over the forecast period.
In South Africa, NCDs (non-communicable diseases) account for 84% of all deaths in persons aged 60 years and above, with ischemic heart disease and stroke being the leading single causes of death in men. The order is reversed in women. Together the diseases account for about one-third of the total deaths. COPD accounts for almost double the number of deaths among men than women. Malignant neoplasms are responsible for 16% of deaths in older men and 10% in older women, with lung cancer as a predominant cause in men and breast cancer in women. Thus, the rising aging population, coupled with the increase in prevalence of various chronic conditions, such as cardiovascular disease, GI diseases, cancer, and NCD’s, is expected to drive the market over the forecast period.
Scope of the Report
As per the scope of this report, minimally invasive surgical devices refer to electrosurgical systems, robot-assisted surgical systems, and surgical equipment, such as needles, retractors, and guide wires, which are used during the minimally invasive procedure.
Key Market Trends
Trocars is the Segment by Surgical Equipment that is Expected to Grow the Fastest During the Forecast Period
The earlier usage of trocars was specifically for the drainage of infected body fluid and gases from the body, but with later innovations, urologists started using trocars for the easy insertion of the surgical scopes inside the body. Currently, trocars are majorly used for laparoscopic procedures, which are associated with the abdominal surgeries that are also referred to as open surgeries. These procedures are made easy with the revolutionary implementation of trocars, which has contributed to the improvement of patient care. Increasing number of laparoscopic surgeries, along with the significance of trocars, is the factor contributing to the growth of this segment in South Africa.
Competitive Landscape
The South African minimally invasive surgical devices market is dominated by few global players. These global enterprises are already competitors in the developed regions, and in South Africa, they operate through regional offices or a network of distributors. In the South African market, which is currently categorized by the presence of high growth opportunities, the existing players are competing with each other on various fronts, such as the introduction of new products, increasing geographical penetration, enhancing distribution channel. The high competition is expected to drive the merger and acquisition activity, thereby, leading to medium market consolidation in few business segments.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Higher Acceptance Rate of Minimally Invasive Procedures Over Traditional Procedures
4.2.2 Improved Patient Quality of Life and Increasing Number of Surgeries Among the Aging Population
4.2.3 Minimally Invasive Surgeries Help Reduce Healthcare Costs and Time
4.2.4 Increasing Prevalence of Lifestyle-related and Chronic Disorders
4.3 Market Restraints
4.3.1 Shortage of Experienced Professionals
4.3.2 Stringent Regulatory Framework and Insurance Plans for Medical Devices are Restraining the Market
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product Type
5.1.1 Surgical Equipment
5.1.1.1 Catheters
5.1.1.2 Staplers
5.1.1.3 Cannula
5.1.1.4 Guide Wires
5.1.1.5 Retractors
5.1.1.6 Needles
5.1.1.7 Trocars
5.1.1.8 Forceps
5.1.1.9 Metal Shafts
5.1.1.10 Other Surgical Instruments and Accessories
5.1.2 Electrosurgical Systems
5.1.2.1 Electrosurgical Accessories
5.1.2.2 Suction Coagulators
5.1.2.3 Pencils
5.1.2.4 Electrodes
5.1.2.5 Bipolar Forceps
5.1.3 Robot-assisted Surgical Systems
5.1.3.1 Da Vinci Systems
5.1.3.2 Zeus Robotic Surgical Systems
5.1.3.3 Other Robot-assisted Surgical Systems
5.1.4 Monitoring and Visualization Equipment
5.1.4.1 MRI Scanners
5.1.4.2 CT Scanners
5.1.4.3 X-ray Equipment
5.1.4.4 Ultrasound Equipment
5.1.4.5 Surgical Visualization Equipment
5.2 By Technology
5.2.1 Laparoscopy
5.2.2 Endoscopy
5.2.3 Arthroscopic Techniques
5.2.4 Ablative Techniques
5.2.4.1 Cryoablation
5.2.4.2 Radio Frequency Ablation
5.2.4.3 Microwave Ablation
5.2.4.4 Embolization
5.2.4.5 Irreversible Electroporation
5.3 By Application
5.3.1 Cardiac Surgery
5.3.2 Urology
5.3.3 Neurosurgery
5.3.4 Gastrointestinal Surgery
5.3.5 Orthopedic
5.3.6 Gynecologic Surgery
5.3.7 Colorectal Surgery
5.3.8 Weight Loss
5.3.9 Lung & Respiratory Care
5.3.10 Ophthalmology
5.3.11 ENT Surgery
5.3.12 Dermatological Surgery
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 GE Healthcare
6.1.3 Intuitive Surgical
6.1.4 Johnson & Johnson
6.1.5 Medtronic PLC
6.1.6 Koninklijke Philips NV
6.1.7 Siemens
6.1.8 Smith & Nephew
6.1.9 Stryker Corporation
6.1.10 Zimmer Biomet
6.1.11 Applied Medical Resources Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Product Type
Surgical Equipment
Catheters
Staplers
Cannula
Guide Wires
Retractors
Needles
Trocars
Forceps
Metal Shafts
Other Surgical Instruments and Accessories
Electrosurgical Systems
Electrosurgical Accessories
Suction Coagulators
Pencils
Electrodes
Bipolar Forceps
Robot-assisted Surgical Systems
Da Vinci Systems
Zeus Robotic Surgical Systems
Other Robot-assisted Surgical Systems
Monitoring and Visualization Equipment
MRI Scanners
CT Scanners
X-ray Equipment
Ultrasound Equipment
Surgical Visualization Equipment
By Technology
Laparoscopy
Endoscopy
Arthroscopic Techniques
Ablative Techniques
Cryoablation
Radio Frequency Ablation
Microwave Ablation
Embolization
Irreversible Electroporation
By Application
Cardiac Surgery
Urology
Neurosurgery
Gastrointestinal Surgery
Orthopedic
Gynecologic Surgery
Colorectal Surgery
Weight Loss
Lung & Respiratory Care
Ophthalmology
ENT Surgery
Dermatological Surgery